Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $23.43 Consensus Target Price from Brokerages

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been given an average recommendation of “Moderate Buy” by the seven analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $23.43.

A number of research firms have commented on TEVA. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Bank of America reduced their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, April 23rd. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently modified their holdings of the stock. Oarsman Capital Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $29,000. Golden State Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $39,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $44,000. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries in the third quarter worth $50,000. Finally, Compagnie Lombard Odier SCmA purchased a new position in Teva Pharmaceutical Industries during the first quarter worth $54,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $15.58 on Wednesday. The company has a market cap of $17.67 billion, a price-to-earnings ratio of -10.74, a P/E/G ratio of 1.44 and a beta of 0.72. The business’s fifty day simple moving average is $15.16 and its two-hundred day simple moving average is $17.53. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Research analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.